C. Rajasoorya, I. M. Holdaway, P. Wrightson, D. J. Scott, and H. K. , Determinants of clinical outcome and survival in acromegaly, Clinical Endocrinology, vol.153, issue.4, pp.95-102, 1994.
DOI : 10.2307/2281868

A. Mestron, S. M. Webb, R. Astorga, P. Benito, M. Catala et al., Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA), Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry, pp.439-446, 2004.
DOI : 10.1530/eje.0.1510439

A. Ben-shlomo, S. Melmed, and . Acromegaly, Acromegaly, Endocrinology and Metabolism Clinics of North America, vol.37, issue.1, p.101, 2008.
DOI : 10.1016/j.ecl.2007.10.002

D. A. Ross and C. B. Wilson, Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients, Journal of Neurosurgery, vol.68, issue.6, pp.854-867, 1988.
DOI : 10.3171/jns.1988.68.6.0854

M. Bluet-pajot, « Physiologie de l'axe somatotrope », in Traité d'endocrinologie, Médecine-Sciences, Flammarion, 2007.

N. Lahlou and M. Roger, « Physiologie de la sécrétion de l'hormone de croissance, Med. Thérapeutique Endocrinol, vol.4, pp.4-14, 2002.

J. S. Bevan, The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.3, 2013.
DOI : 10.1210/jc.2004-1093

P. Jacquet, A. Saveanu, and A. Barlier, «New somatostatin analogs : therapeutical perspectives, Métab. Hormon. Diabètes et Nut, vol.10, pp.3-4, 2006.

L. J. Hofland and S. W. Lamberts, Somatostatin receptor subtype expression in human tumors, Annals of Oncology, vol.12, issue.suppl 2, pp.31-36, 2000.
DOI : 10.1093/annonc/12.suppl_2.S31

G. Lugo, Clinical Manifestations and Diagnosis of Acromegaly, International Journal of Endocrinology, vol.47, issue.2, 2012.
DOI : 10.1210/jc.2007-1191

S. Melmed and . Acromegaly, Acromegaly, New England Journal of Medicine, vol.355, issue.24, pp.2558-257391, 2006.
DOI : 10.1056/NEJMra062453

URL : https://hal.archives-ouvertes.fr/hal-00017712

A. Colao, P. Marzullo, C. Di-somma, and G. Lombardi, Growth hormone and the heart, Growth hormone and the heart, pp.137-154, 2001.
DOI : 10.1210/en.137.5.1798

P. Kamenicky, S. Viengchareun, A. Blanchard, G. Meduri, P. Zizzari et al., Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in Acromegaly, Endocrinology, vol.149, issue.7, pp.3294-3305, 2008.
DOI : 10.1210/en.2008-0143

URL : https://hal.archives-ouvertes.fr/inserm-00266634

A. M. Pereira, S. J. Van-thiel, J. R. Lindner, F. Roelfsema, E. E. Van-der et al., Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.1, pp.71-75, 2004.
DOI : 10.1210/jc.2003-030849

M. Matta and P. Caron, Acromegalic Cardiomyopathy: A Review of the Literature, Pituitary, vol.6, issue.4, pp.203-207, 2003.
DOI : 10.1023/B:PITU.0000023427.31609.a2

P. Attal and P. Chanson, Endocrine Aspects of Obstructive Sleep Apnea, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.2, pp.483-495, 2010.
DOI : 10.1210/jc.2009-1912

M. V. Davi, L. Dalle-carbonare, A. Giustina, M. Ferrari, A. Frigo et al., Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease, European Journal of Endocrinology, vol.159, issue.5, pp.533-540, 2008.
DOI : 10.1530/EJE-08-0442

S. Dostalova, K. Sonka, Z. Smahel, V. Weiss, J. Marek et al., Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly, European Journal of Endocrinology, vol.144, issue.5, pp.491-497, 2001.
DOI : 10.1530/eje.0.1440491

C. Cortet, « Savoir reconnaître les signes de l'acromégalie -Apnées du sommeil et acromégalie

S. Melmed, CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem?, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.7, pp.2929-2934, 2001.
DOI : 10.1210/jcem.86.7.7635

S. M. Orme, R. J. Mcnally, R. A. Cartwright, and P. E. Belchetz, Mortality and Cancer Incidence in Acromegaly, The Journal of Urology, vol.83, issue.8, pp.2730-2734, 1998.
DOI : 10.1097/00005392-199904000-00103

P. J. Jenkins and M. Besser, CLINICAL PERSPECTIVE: Acromegaly and Cancer: A Problem, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.7, pp.2935-294191, 2001.
DOI : 10.1210/jcem.86.7.7634

I. M. Holdaway, M. J. Bolland, and G. D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly, European Journal of Endocrinology, vol.159, issue.2, pp.89-95, 2008.
DOI : 10.1530/EJE-08-0267

A. S. Bates, W. Van-'t-hoff, J. M. Jones, R. N. Clayton-harris, and R. A. , Does treatment of acromegaly affect life expectancy?, Metabolism, vol.44, pp.1-5, 1995.
DOI : 10.1016/0026-0495(95)90303-8

J. A. Turner, J. M. Wass, and . Wardlaw, « Primary medical therapy for acromegaly : an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor I, and tumor size, J. Clin. Endocrinol. Metab, vol.87, issue.10, pp.4554-4563, 2002.

I. M. Holdaway, Excess Mortality in Acromegaly, Excess mortality in acromegaly, pp.166-172, 2007.
DOI : 10.1159/000110617

I. M. Holdaway, R. C. Rajasoorya, and G. D. Gamble, Factors Influencing Mortality in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.2, pp.667-674, 2004.
DOI : 10.1210/jc.2003-031199

O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke, Mortality in Acromegaly: A Metaanalysis, Mortality in acromegaly: a metaanalysis, pp.61-67, 2008.
DOI : 10.1210/jc.2007-1191

W. Te, H. D. Lin, R. A. Lu, M. L. Wang, R. L. Chen et al., « The role of insulinlike growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery, pp.411-415, 2010.

M. Bayle, D. Chevenne, B. Dousset, N. Lahlou, C. Massart et al., « Recommandations pour l'harmonisation des techniques de dosage sérique d'hormone de croissance, Ann. Biol. Clin, vol.62, pp.155-163, 2004.

J. Kreutzer, M. L. Vance, M. B. Lopes, and E. R. Laws, Surgical Management of GH-Secreting Pituitary Adenomas: An Outcome Study Using Modern Remission Criteria, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.9, pp.4072-4077, 2001.
DOI : 10.1210/jcem.86.9.7819

A. Giustina, P. Chanson, M. D. Bronstein, A. Klibanski, S. Lamberts et al., A Consensus on Criteria for Cure of Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.7, pp.3141-3148, 2010.
DOI : 10.1210/jc.2009-2670

U. Salmi, J. Stenman, E. Viikari, and . Voutilainen, « A nationwide survey of mortality in acromegaly, J. Clin. Endocrinol. Metab, vol.90, issue.7, pp.4081-4086, 2005.

N. R. Biermasz, F. W. Dekker, A. M. Pereira, S. W. Van-thiel, P. J. Schutte et al., Roelfsema, « Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor i measurements, p.91

P. Chanson, J. Bertherat, A. Beckers, H. Bihan, T. Brue et al., Consensus fran??ais sur la prise en charge de l???acrom??galie, Consensus français sur la prise en charge de l'acromégalie, pp.9-22, 2009.
DOI : 10.1016/j.ando.2008.12.010

S. Ahmed, M. Elsheikh, I. M. Stratton, R. C. Page, C. B. Adams et al., Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience, Clinical Endocrinology, vol.39, issue.5, pp.561-567, 1999.
DOI : 10.1046/j.1365-2265.1996.8370847.x

P. A. Seidman, W. A. Kofke, R. Policare, and M. Young, Anaesthetic complications of acromegaly, Anaesthetic complications of acromegaly. », pp.179-182, 2000.
DOI : 10.1093/oxfordjournals.bja.a013400

N. R. Biermasz, H. Van-dulken, and F. Roelfsema, Direct Postoperative and Follow-Up Results of Transsphenoidal Surgery in 19 Acromegalic Patients Pretreated with Octreotide Compared to Those in Untreated Matched Controls, The Journal of Clinical Endocrinology & Metabolism, vol.84, issue.10, pp.3551-3555, 1999.
DOI : 10.1210/jcem.84.10.6027

P. Nomikos, M. Buchfelder, and R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure', European Journal of Endocrinology, vol.152, issue.3, pp.379-387, 2005.
DOI : 10.1530/eje.1.01863

J. A. Jane, R. M. Starke, M. A. Elzoghby, D. L. Reames, S. C. Payne et al., Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9, pp.2732-2740, 2011.
DOI : 10.1210/jc.2011-0554

A. Bourdelot, J. Coste, V. Hazebroucq, S. Gaillard, L. Cazabat et al., Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly, European Journal of Endocrinology, vol.150, issue.6, pp.763-771, 2004.
DOI : 10.1530/eje.0.1500763

P. U. Freda, S. L. Wardlaw, and K. D. Post, Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly, Journal of Neurosurgery, vol.89, issue.3, pp.353-358, 1998.
DOI : 10.3171/jns.1998.89.3.0353

A. Abosch, J. B. Tyrrell, K. R. Lamborn, L. T. Hannegan, C. B. Applebury et al., Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term Results, The Journal of Clinical Endocrinology & Metabolism, vol.83, issue.10, pp.3411-3418, 1998.
DOI : 10.1210/jcem.83.10.5111

P. M. Stewart, K. F. Kane, S. E. Stewart, I. Lancranjan, and M. C. Sheppard, « Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly, J. Clin. Endocrinol. Metab, vol.80, issue.11, pp.3267-3272, 1995.

P. Grass, P. Marbach, C. Bruns, I. Lancranjan, and L. Sandostatin, Sandostatin?? LAR?? (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships, Metabolism, vol.45, pp.27-30, 1996.
DOI : 10.1016/S0026-0495(96)90075-X

M. C. Sheppard, Primary medical therapy for acromegaly, Clinical Endocrinology, vol.39, issue.4, pp.387-399, 2003.
DOI : 10.1046/j.1365-2265.1996.8080817.x

Y. Lorcy, S. Dejager, P. Chanson, F. Octreotide, and L. Group, « Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly, Pituitary, vol.3, issue.3, pp.193-197, 2000.
DOI : 10.1023/A:1011416112730

C. B. Newman, Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study., The Journal of Clinical Endocrinology & Metabolism, vol.80, issue.9, pp.2768-2775, 1995.
DOI : 10.1210/jcem.80.9.7673422

R. Murray and S. Melmed, A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.2957-2968, 2008.
DOI : 10.1210/jc.2008-0027

A. Colao, D. Ferone, P. Marzullo, P. Cappabianca, S. Cirillo et al., Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.6, pp.2779-2786, 2001.
DOI : 10.1210/jc.86.6.2779

S. M. Carlsen, J. Svartberg, T. Schreiner, S. Aanderud, O. Johannesen et al., Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure, Clinical Endocrinology, vol.87, issue.6, pp.736-743, 2011.
DOI : 10.1111/j.1365-2265.2011.03982.x

T. Abe and D. K. Ludecke, Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre, European Journal of Endocrinology, vol.145, issue.2, pp.137-145, 2001.
DOI : 10.1530/eje.0.1450137

D. Salle, A. Giustina, and C. Carella, « Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly, Clin. Endocrinol, vol.56, pp.65-71, 2002.

P. U. Freda, Somatostatin Analogs in Acromegaly, Somatostatin analog in acromegaly, pp.3013-3018, 2002.
DOI : 10.1210/jcem.87.7.8665

A. K. Flogstad, J. Hase, and B. Soren, Sandostatin LAR in Acromegalic Patients: Long Term Treatment, The Journal of Clinical Endocrinology & Metabolism, vol.82, issue.1, pp.23-28, 1997.
DOI : 10.1210/jcem.82.1.3572

P. Chanson, B. Delemer, and T. Brue, Efficacit?? et tol??rance du pegvisomant en pratique r??elle??: analyse interm??diaire de l?????tude ACROstudy France, Annales d'Endocrinologie, vol.75, issue.5-6, pp.5-6, 2014.
DOI : 10.1016/j.ando.2014.07.168

F. Castinetti, I. Morange, H. Dufour, J. Regis, and T. Brue, Radiotherapy and radiosurgery in acromegaly, Pituitary, vol.4, issue.Suppl 3, pp.3-10, 2009.
DOI : 10.1007/s11102-007-0078-y

P. Colin, N. Jovenin, B. Delemer, J. Caron, H. Grulet et al., Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: A prospective study of 110 patients, International Journal of Radiation Oncology*Biology*Physics, vol.62, issue.2, pp.333-341, 2005.
DOI : 10.1016/j.ijrobp.2004.09.058

A. Colao, D. Ferone, P. Cappabianca, M. L. Del-basso-de-caro, P. Marzullo et al., Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.82, issue.10, pp.3308-3314, 1997.
DOI : 10.1210/jcem.82.10.4283

A. L. Barkan, R. V. Lloyd, W. F. Chandler, M. K. Hatfield, S. S. Gebarski et al., Preoperative Treatment of Acromegaly with Long-Acting Somatostatin Analog SMS 201-995: Shrinkage of Invasive Pituitary Macroadenomas and Improved Surgical Remission Rate*, The Journal of Clinical Endocrinology & Metabolism, vol.67, issue.5, pp.1040-1048, 1988.
DOI : 10.1210/jcem-67-5-1040

M. L. Jackson, A. Vance, L. Barkan, D. L. Frohman, and . Kleinberg, « Octreotide as primary therapy for acromegaly, J. Clin. Endocrinol. Metab, vol.83, issue.88, pp.3034-304091, 1998.

R. Kristof, B. Stoffel-wagner, D. Klingmüller, and J. Schramm, Does Octreotide Treatment Improve the Surgical Results of Macro-Adenomas in Acromegaly? A Randomized Study, Acta Neurochirurgica, vol.141, issue.4, pp.399-405, 1999.
DOI : 10.1007/s007010050316

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

L. Zhang, X. Wu, Y. Yan, J. Qian, Y. Lu et al., Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis, Brain and Development, vol.37, issue.2, pp.181-190, 2015.
DOI : 10.1016/j.braindev.2014.04.009

A. Colao, P. Cappabianca, P. Caron, E. De-menis, A. J. Farrall et al., surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study, Clinical Endocrinology, vol.47, issue.5, pp.757-768, 2009.
DOI : 10.1111/j.1365-2265.2008.03441.x

S. M. Carlsen, M. Lund-johansen, T. Schreiner, S. Aanderud, O. Johannesen et al., Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.2984-2990, 2008.
DOI : 10.1210/jc.2008-0315

M. Shen, X. Shou, Y. Wang, Z. Zhang, J. Wu et al., Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study, Endocrine Journal, vol.57, issue.12, pp.12-1035, 2010.
DOI : 10.1507/endocrj.K10E-203

Z. Mao, Y. Zhu, and H. Tang, Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial, European Journal of Endocrinology, vol.162, issue.4, pp.661-666, 2010.
DOI : 10.1530/EJE-09-0908

Z. Li, Z. Quan, H. L. Tian, and M. Cheng, Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma, Journal of International Medical Research, vol.93, issue.2, pp.517-524, 2012.
DOI : 10.1177/147323001204000213

V. Nunes, J. M. Correa, M. E. Puga, E. M. Silva, and C. L. Boguszewski, Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system, Pituitary, vol.64, issue.4, pp.500-508, 2015.
DOI : 10.1007/s11102-014-0602-9

S. L. Fougner, J. Bollerslev, J. Svartberg, M. Oksnes, J. Cooper et al., Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial, European Journal of Endocrinology, vol.171, issue.2, pp.229-235, 2014.
DOI : 10.1530/EJE-14-0249

F. Sangiao-alvarellos and . Cordido, « Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome : a systematic review and meta-analysis, Plosone, vol.8, issue.4, 2013.

M. Mercado, F. Borges, H. Bouterfa, T. C. Chang, A. Chervin et al., (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clinical Endocrinology, vol.29, issue.6, pp.859-868, 2007.
DOI : 10.1210/jc.85.2.781

R. Cozzi, M. Montini, R. Attanasio, M. G. Albazzi, S. Lasio et al., Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.4, pp.1397-1403, 2006.
DOI : 10.1210/jc.2005-2347

J. Maiza, D. Vezzosi, M. Matta, F. Donadille, F. Loubes-lacroix et al., Long-term (up to 18??years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa, Clinical Endocrinology, vol.87, issue.Suppl. 1, pp.282-289
DOI : 10.1111/j.1365-2265.2007.02878.x

A. Colao, S. A. Renata, M. Galdiero, G. Lombardi, and R. Pivonello, Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.10, pp.3746-3756, 2009.
DOI : 10.1210/jc.2009-0941

DOI : 10.4158/EP14575.DSCR